Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Orchestra BioMed Holdings, Inc. - Ordinary Shares (NQ:OBIO)

5.725 -0.185 (-3.13%)
Delayed Quote Updated: 3:14 PM EST, Nov 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Orchestra BioMed Holdings, Inc. - Ordinary Shares

< Previous 1 2 3 4 5 Next >
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Power Solutions International Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Orchestra BioMed to Present at Upcoming Investor Conferences
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory Board
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Announces Data Demonstrating Favorable Impact of AVIM Therapy on Diastolic Dysfunction, a Key Driver of Heart Failure Progression, will be Presented as Late-Breaking Science at the THT 2025 Conference
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
This Kopin Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Orchestra BioMed Announces AVIM Therapy Program Presentations at ICI Meeting
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed to Participate in the Piper Sandler 36th Annual Healthcare Conference
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Reports Third Quarter 2024 Financial Results and Provides a Business Update
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed to Participate in Jefferies London Healthcare Conference
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
OBIO Stock Earnings: Orchestra BioMed Hldgs Misses EPS, Beats Revenue for Q2 2024 ↗
OBIO stock results show that Orchestra BioMed Hldgs missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Announces Appointment of Cardiovascular Device Industry Expert John Mack to Board of Directors
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Precision Neuroscience Expands Executive Team as Brain–Computer Interface Industry Rapidly Advances
Jayme Strauss and Mike Kaswan join as Chief Clinical and Commercial Officer and Chief Financial Officer, respectively, as the company progresses toward FDA clearance 
From Precision Neuroscience
Via GlobeNewswire
News headline image
Orchestra BioMed Announces Further Details on In-Person R&D Day in New York Featuring Key Opinion Leaders to Discuss AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed to Participate in Jefferies Global Healthcare Conference
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
OBIO Stock Earnings: Orchestra BioMed Hldgs Beats EPS, Misses Revenue for Q1 2024 ↗
OBIO stock results show that Orchestra BioMed Hldgs beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed to Host In-Person R&D Day in New York on AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
OBIO Stock Earnings: Orchestra BioMed Hldgs Beats EPS, Misses Revenue for Q4 2023 ↗
OBIO stock results show that Orchestra BioMed Hldgs beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue® SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed to Participate in Upcoming Investor Conferences
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with AVIM Therapy for Over 3 Years
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.